People

Neurogene board director and independent consultant for biopharmaceutical companies. Previously a Samsara BioCapital partner from October 2017 through April 2025, with earlier investing roles at Sofinnova and Novo and research at Roche focused on psychiatric and neurodegenerative disease targets. Holds Wake Forest pharmacology, Kellogg MBA and Connecticut College degrees.